ArticleLife (Basel, Switzerland)2023

The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus.

Teodor Salmen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.